Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium Avium Infection in a Patient with Anti-Interferon-γ Autoantibody

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2017 Aug 6

PMID 28779413

Citations 30

Authors

Yusuke Koizumi

Takuro Sakagami

Naoya Nishiyama

Jun Hirai

Yuta Hayashi

Nobuhiro Asai

Yuka Yamagishi

Hideo Kato

Mao Hagihara

Daisuke Sakanashi

Hiroyuki Suematsu

Kenji Ogawa

Hiroshige Mikamo

Affiliations

Soon will be listed here.

Abstract

A 67-year-old Japanese female with back pain and severe cachexia visited our hospital. The diagnosis was disseminated Mycobacterium avium complex infection (dMAC) with multiple bone involvement. Anti-mycobacterial chemotherapy was started, but fever persisted and dislocation of cervical vertebrae has made her bedridden. Because anti-interferon (IFN)-γ autoantibody was positive, four doses of rituximab 375 mg/m, every 7 day, were administered. Soon after treatment, progression of osteolytic lesions and wasting has stopped. We proved that rituximab has recovered IFN-γ signaling as shown by IFN-γ-induced STAT1 phosphorylation. It can be a promising option for dMAC cases with anti-IFN-γ autoantibody.

Citing Articles

Multiple pathogen infections accompanied with ocular pathologies in a patient with high-titer Anti-IFN-γ autoantibodies: a case report.

Wu S, Liang S, Liang H, Ning Y, Li X, He Z BMC Infect Dis. 2024; 24(1):1319.

PMID: 39563232 PMC: 11577644. DOI: 10.1186/s12879-024-10217-2.

A patient with positive anti-IFN-γ autoantibody and monoclonal gammaglobulinemia masquerading as multiple myeloma: Case report and literature review.

An R, Liu Z, Luo F, Yan Z, Wang Y, Sun H Clin Case Rep. 2024; 12(9):e9446.

PMID: 39301094 PMC: 11410870. DOI: 10.1002/ccr3.9446.

Clinical immunological characteristics of anti-interferon-γ autoantibodies syndrome: a 3 year prospective cohort study.

Liang S, Liang H, Huang X, Liang X, Chen N, Xiao R Emerg Microbes Infect. 2024; 13(1):2396887.

PMID: 39178284 PMC: 11378669. DOI: 10.1080/22221751.2024.2396887.

A homogeneous bioluminescent inhibition immunoassay to detect anti-interferon gamma antibodies.

Bradhurst P, Stoyanov A, Nithichanon A, Bundell C, Urriola N Clin Exp Immunol. 2024; 218(3):283-290.

PMID: 38975719 PMC: 11557142. DOI: 10.1093/cei/uxae055.

Interferon Upregulation Associates with Insulin Resistance in Humans.

Adeva-Andany M, Carneiro-Freire N, Castro-Quintela E, Ameneiros-Rodriguez E, Adeva-Contreras L, Fernandez-Fernandez C Curr Diabetes Rev. 2024; 21(3):86-105.

PMID: 38500280 DOI: 10.2174/0115733998294022240309105112.

References

Barcellini W, Zaja F, Zaninoni A, Imperiali F, Di Bona E, Fattizzo B . Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013; 91(6):546-51. DOI: 10.1111/ejh.12199. View

Browne S, Zaman R, Sampaio E, Jutivorakool K, Rosen L, Ding L . Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012; 119(17):3933-9. PMC: 3350360. DOI: 10.1182/blood-2011-12-395707. View

Horsburgh Jr C . Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324(19):1332-8. DOI: 10.1056/NEJM199105093241906. View

Sridhar S, Fung K, Chan J, Lam J, Yip E, Hung I . High recurrence rate supports need for secondary prophylaxis in non-HIV patients with disseminated mycobacterium avium complex infection: a multi-center observational study. BMC Infect Dis. 2016; 16:74. PMC: 4748557. DOI: 10.1186/s12879-016-1411-8. View

Shimizu H, Mizuno Y, Nakamura I, Fukushima S, Endo K, Matsumoto T . Vertebral osteomyelitis caused by non-tuberculous mycobacteria: case reports and review. J Infect Chemother. 2013; 19(5):972-7. DOI: 10.1007/s10156-013-0550-8. View

Bustamante J, Boisson-Dupuis S, Abel L, Casanova J . Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol. 2014; 26(6):454-70. PMC: 4357480. DOI: 10.1016/j.smim.2014.09.008. View

Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G . Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013; 22(11):1142-9. DOI: 10.1177/0961203313503912. View

Lai C, Lee L, Ding L, Yu C, Hsueh P, Yang P . Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect. 2005; 53(2):77-84. DOI: 10.1016/j.jinf.2005.10.009. View

Browne S, Burbelo P, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw P . Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012; 367(8):725-34. PMC: 4190026. DOI: 10.1056/NEJMoa1111160. View

10.

Hoshina T, Takada H, Sasaki-Mihara Y, Kusuhara K, Ohshima K, Okada S . Clinical and host genetic characteristics of Mendelian susceptibility to mycobacterial diseases in Japan. J Clin Immunol. 2011; 31(3):309-14. DOI: 10.1007/s10875-010-9498-y. View

11.

Baerlecken N, Jacobs R, Stoll M, Schmidt R, Witte T . Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. Clin Infect Dis. 2009; 49(7):e76-8. DOI: 10.1086/605581. View

12.

Pruetpongpun N, Khawcharoenporn T, Damronglerd P, Suthiwartnarueput W, Apisarnthanarak A, Rujanavej S . Disseminated Talaromyces marneffei and Mycobacterium abscessus in a Patient With Anti-Interferon-γ Autoantibodies. Open Forum Infect Dis. 2016; 3(2):ofw093. PMC: 4943537. DOI: 10.1093/ofid/ofw093. View

13.

Nakayama M, Oda H, Nakagawa K, Yasumi T, Kawai T, Izawa K . Accurate clinical genetic testing for autoinflammatory diseases using the next-generation sequencing platform MiSeq. Biochem Biophys Rep. 2017; 9:146-152. PMC: 5614572. DOI: 10.1016/j.bbrep.2016.12.002. View

14.

Czaja C, Merkel P, Chan E, Lenz L, Wolf M, Alam R . Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody. Clin Infect Dis. 2013; 58(6):e115-8. PMC: 3935498. DOI: 10.1093/cid/cit809. View

15.

Doffinger R, Helbert M, Barcenas-Morales G, Yang K, Dupuis S, Ceron-Gutierrez L . Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2003; 38(1):e10-4. DOI: 10.1086/380453. View

16.

Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T . Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014; 20(1):52-6. DOI: 10.1016/j.jiac.2013.08.003. View

17.

Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S . Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005; 115(9):2480-8. PMC: 1190367. DOI: 10.1172/JCI19316. View

18.

Chi C, Lin C, Ho M, Ding J, Huang W, Shih H . Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore). 2016; 95(25):e3927. PMC: 4998320. DOI: 10.1097/MD.0000000000003927. View

19.

Iorio R, Damato V, Alboini P, Evoli A . Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2014; 262(5):1115-9. DOI: 10.1007/s00415-014-7532-3. View